Watch the video and download the slides


Practical considerations when sequencing treatments for mCRPC patients in clinical practice

GU NURSES CONNECT expert Joanne Chien provides an overview of practical considerations when sequencing treatments for mCRPC patients in clinical practice and how recent real-world data can help guide these decisions.

Watch the video and download the slides.

Hi, my name is Joanne Chien, Nurse Practitioner at Stanford Health Care in California, USA.

Today I will be discussing practical considerations when sequencing treatments for metastatic CRPC patients, reviewing recent real-world data and different treatment sequences and helping patients to understand what side effects to expect, that may be related to their prior treatment as well as current treatment.

Real-world data guiding treatment sequencing strategies in metastatic CRPC

Sequencing treatments in metastatic CRPC has been revolutionised, due to the rapid evolving treatment options, and the early use of the novel hormonal therapies. The real-world data is valuable in guiding sequencing strategies, as it is reflective of the patient population that we see in our clinical practice.

Real-world data from a study in the United States, showed that overall survival was higher in patients receiving multiple life-prolonging therapies. However, more than 50% of the patients never received subsequent treatment, after only the first-line therapy. And only 60% of the patients received the bone-health agent, which is imperative to prevent pathologic fracture in patients with metastatic CRPC.

The back-to-back use of abiraterone and enzalutamide was also common, despite the evidence of cross-resistance and limited efficacy. To overcome this cross-resistance, studies recommend using a therapy with a different mechanism-of-action as presented in the CARD trial.

For patients who have received a prior docetaxel and an AR-targeted agent, now using cabazitaxel significantly improved clinical outcomes, and reduced pain, instead of switching to another novel hormonal therapy. This data was also validated by the real-world analysis presented at ESMO virtual congress 2020 by Doctor de Wit. Patients may express concerns over the side effects that they may have had with prior chemotherapy, such as fatigue, neutropenia, peripheral neuropathy that may have impacted their quality of life. And they may be worried about the risk of infection, particularly during this COVID pandemic.

Evidenced-based care and supporting patients in shared decision-making

As a GU oncology nurse, we’re here to provide evidenced-based care and to support our patients in shared decision-making. Helping patients understand that using cabazitaxel in this space is safe, effective, and pretty well tolerated. It is often given with the growth factor to reduce risk of neutropenia. 

Radium-223 is a good option to improve clinical outcomes in patients with symptomatic bony metastasis. Recent real-world data has also shown improved overall survival in metastatic CRPC patients with early use of radium-223, compared to later use.

Most recently the data from the VISION trial demonstrated that lutetium-PSMA prolonged overall survival compared to standard of care, and may be a future treatment option in metastatic CRPC, after both hormonal therapies and taxane chemotherapy.

Knowing the patients’ genomic status is also important for potential targeted therapies, such as PARP-inhibitor for patients with homologous recombination repair mutation, and pembrolizumab in patients with high microsatellite instability.

And, as always, clinical trials should be considered for all our patients. The goal is to deliver as many effective life-prolonging therapies as possible, preferably sequencing treatment with a different mechanism of action, while balancing quality of life.

For more information and to download the slides, please go to gunursesconnect.cor2ed.com. Thank you for listening on behalf of GU NURSES CONNECT.

Joanne Chien graduated with a Bachelor of Science in Nursing from San Jose State University with Cum Laude Honor and then trained and worked as a Registered Nurse for 5 years on a Medical-Surgical unit at Stanford Hospital.  In 2008 she received her Master of Science in Nursing with Gerontological Nurse Practitioner degree from the University of California, San Francisco.  She has worked as a Nurse Practitioner since 2010 with the first four years in the Community Living Center at Veterans Affairs Health Care System managing patients with complex medical and mental health conditions and providing inpatient Hospice care.  Joanne returned to Stanford Hospital in 2014 and works as a Nurse Practitioner in Urologic Medical Oncology specializing in treating urologic cancers, managing treatment-related side effects and participating in clinical trials as a sub-investigator.   Joanne was born and raised in Taiwan and is bilingual in Mandarin and English.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
podcast Podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
ELPA
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.